Yili Chuanning Biotechnology Co.,Ltd. (SHE:301301)

Market Cap	23.01B -19.5%
Revenue (ttm)	4.62B -19.8%
Net Income	769.01M -45.1%
EPS	0.34 -46.0%
Shares Out	2.23B
PE Ratio	30.35
Forward PE	22.43
Dividend	0.17 (1.68%)
Ex-Dividend Date	Jun 10, 2025

Volume	10,891,800
Average Volume	18,226,677
Open	10.50
Previous Close	10.51
Day's Range	10.28 - 10.50
52-Week Range	9.71 - 14.74
Beta	0.26
RSI	42.18
Earnings Date	Mar 31, 2026

About SHE:301301

Yili Chuanning Biotechnology Co.,Ltd., together with its subsidiaries, engages in the research, development, and industrialization of bio-fermentation technology and synthetic biology products in China and internationally. It offers antibiotic intermediates comprising erythromycin thiofluorate; cephalosporin intermediates consisting of 7-aminocephalosporanic acid (7-ACA), 7-amino-3-deacetoxycephalosporinic acid (7-ADCA), and D-7ACA; penicillin intermediates, such as 6-aminopenicillanic acid (6-APA) and penicillin G potassium salt; ursodeoxychol...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2010
• Employees: 3,126
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 301301

Financial Performance

In 2025, SHE:301301's revenue was 4.62 billion, a decrease of -19.83% compared to the previous year's 5.76 billion. Earnings were 769.01 million, a decrease of -45.08%.